NCT03710317View on ClinicalTrials.gov

Carbetocin Versus Buccal Misoprostol Plus IV Tranexamic Acid for Prevention of Postpartum Hemorrhage at Cesarean Section

NACompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

May 30, 2020

Study Completion Date

August 1, 2020

Conditions
Cesarean Section Complications
Interventions
DRUG

carbetocin

100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby

DRUG

Tranexamic Acid

1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.

DRUG

misoprostol

Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision

Trial Locations (1)

81528

Aswan University, Aswān

All Listed Sponsors
lead

Aswan University Hospital

OTHER

NCT03710317 - Carbetocin Versus Buccal Misoprostol Plus IV Tranexamic Acid for Prevention of Postpartum Hemorrhage at Cesarean Section | Biotech Hunter | Biotech Hunter